English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Two highly sensitive spectrophotometric methods are proposed for the  quantification of atenolol (ATN) in pure drug as well as in pharmaceutical  formulations. The methods are based on the bromination reaction of ATN with a  known excess of bromate-bromide mixture in acid medium followed by the  determination of unreacted bromine. The residual bromine is determined by its  reaction with excess iodide and the liberated iodine (I3□) is either measured  at 360 nm (method A) or reacted with starch followed by the measurement of  the starch-iodine chromogen at 570 nm (method B). Under the optimum  conditions, ATN could be assayed in the concentration ranges of 0.5-9.0 and  0.3-6.0μg mL-1 for method A and method B, respectively, with corresponding  molar absorptivity values of 2.36×104 and 2.89×104 L/mol.cm. Sandell’s  sensitivity values are found to be 0.0113 and 0.0092 μg/cm2 for method A and  method B, respectively. The proposed methods were successfully applied to the  analysis of different commercial brands of pharmaceutical formulations and  the results obtained by the proposed methods were in good agreement with  those obtained using the reference method. The reliability of the methods was  further ascertained by recovery studies using standard- addition method

Application of bromate-bromide mixture as a green brominating agent for the spectrophotometric determination of atenolol in pharmaceuticals